BeStock  
Stocks › Biotechnology › ADRX

Adarx Pharmaceuticals ADRX

US equityMarket cap rank #2910Biotechnology
$12.79 −$1.37 (-9.68%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $12.79 0.00%
Open$14.03
Prev close$14.16
Day range$12.63 – $14.87
Volume708.8K
Market cap$1.42B
P/E (TTM)–
Dividend yield–

Fundamentals

Latest reported quarter: Q2, ended Jun 2026

Revenue$746,000.00+258.7% YoY
Operating profit-$29.89M-41.5% YoY
Net profit-$25.76M-42.4% YoY
Diluted EPS-$0.24-0.4% YoY
Free cash flow-$27.56M-108.8% YoY
Operating cash flow-$27.19M

Revenue, last 4 quarters

$0.0Mar '25$208.0KJun '25$2.1MMar '26$746.0KJun '26

Net profit, last 4 quarters

$-15.6MMar '25$-18.1MJun '25$-22.7MMar '26$-25.8MJun '26

Diluted EPS by quarter

-0.21Mar '25-0.24Jun '25-0.21Mar '26-0.24Jun '26

Free cash flow by quarter

$-13.2MMar '25$312.5MJun '25$-22.8MMar '26$-27.6MJun '26

Profitability & balance sheet

Operating margin-1,735.0%
Net margin-1,434.1%
Return on assets-19.3%
Current ratio12.98
Liabilities / assets155.0%
Cash & investments$427.25M
Total debt$5.19M
Net cash (debt)$422.07M

Cash flow

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
-Change in Prepaid Assets -$1.37M $493,000.00 -$3.69M -$4.50M $1.75M
Change in Working Capital -$3.59M -$1.36M $329.81M $330.53M $1.64M
Depreciation & Depletion & Amortization $735,000.00 $720,000.00 $2.33M $626,000.00 $514,000.00
Net Income from Continuing Operations -$25.76M -$22.67M -$73.09M -$18.09M -$15.55M
Net cash flow from continuing operations -$27.19M -$22.68M $262.29M $313.44M -$12.71M
Operating Cash Flow -$27.19M -$22.68M $262.29M $313.44M -$12.71M
-Change in Payables and Accrued Expense $514,000.00 $730,000.00 $4.36M $698,000.00 $1.33M
Free Cash Flow -$27.56M -$22.76M $259.35M $312.45M -$13.20M
Effect of Exchange Rate Changes $47,000.00 $61,000.00 $23,000.00 $18,000.00 -$6,000.00
Net Change in Cash -$5.42M -$2.72M $52.46M $50.36M $1.24M
Net Investment Purchase and Sale $22.13M $20.04M -$206.99M -$262.17M $14.44M
Financing Cash Flow $6,000.00 $2,000.00 $97,000.00 $83,000.00 $0.00
Net Cash Flow from Continuing Financing Activities $6,000.00 $2,000.00 $97,000.00 $83,000.00 $0.00
Beginning Cash Balance $63.86M $66.52M $14.03M $15.27M $14.03M
Net PPE Purchase and Sale -$367,000.00 -$77,000.00 -$2.94M -$992,000.00 -$497,000.00
Ending Cash Balance $58.48M $63.86M $66.52M $65.65M $15.27M
Net Cash Flow from Continuing Investing Activities $21.76M $19.96M -$209.93M -$263.17M $13.94M
Proceeds from Stock Option Exercised $6,000.00 $2,000.00 $97,000.00 $83,000.00 $0.00
Net cash flow from investing $21.76M $19.96M -$209.93M -$263.17M $13.94M
-Change In Other Working Capital -$746,000.00 -$2.14M $331.55M – –
-Change in Other Current Liabilities -$430,000.00 -$412,000.00 -$862,000.00 -$370,000.00 -$128,000.00
-Change in Other Current Assets -$1.57M -$30,000.00 -$1.55M -$91,000.00 -$1.32M

Income statement

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2025 Q2 2025 Q1
Non-Operating Interest Income $3.78M $3.98M $13.64M $2.48M $2.27M
Other Income (Expense) $355,000.00 $411,000.00 $1.64M $553,000.00 $72,000.00
Other Non-Operating Income (Expenses) $355,000.00 $411,000.00 $1.64M $553,000.00 $72,000.00
Pretax Profit -$25.76M -$22.67M -$73.09M -$18.09M -$15.55M
Net Income to Parent Company -$25.76M -$22.67M -$73.09M -$18.09M -$15.55M
Net Income to Common Stockholders -$25.76M -$22.67M -$73.09M -$18.09M -$15.55M
Basic EPS -$0.24 -$0.21 -$0.97 -$0.24 -$0.21
Diluted EPS -$0.24 -$0.21 -$0.97 -$0.24 -$0.21
Net Non-Operating Interest Income (Expense) $3.78M $3.98M $13.64M $2.48M $2.27M
Operating Profit -$29.89M -$27.06M -$88.37M -$21.12M -$17.89M
Profit from Continuing Operations -$25.76M -$22.67M -$73.09M -$18.09M -$15.55M
Total Revenue as Reported $746,000.00 $2.14M $3.45M $208,000.00 $0.00
Total Operating Revenue $746,000.00 $2.14M $3.45M $208,000.00 $0.00
Operating Expense $30.64M $29.20M $91.81M $21.33M $17.89M
Selling and Admin Expenses $5.90M $5.62M $20.30M $4.26M $5.00M
-General & Admin Expense $5.90M $5.62M $20.30M $4.26M $5.00M
Research & Development $24.74M $23.58M $71.51M $17.07M $12.89M
Net Profit -$25.76M -$22.67M -$73.09M -$18.09M -$15.55M

Balance sheet

Line item 2026 Q2 2026 Q1 2025 ANNUAL 2024 ANNUAL
Cash and Cash Equivalents & Short-Term Investments $427.25M $455.82M $480.00M $219.48M
Gains/Losses Not Affecting Retained Earnings -$783,000.00 $306,000.00 $1.96M $335,000.00
Retained Earnings -$269.13M -$243.37M -$220.70M -$147.61M
Additional Paid-In Capital $18.86M $17.33M $16.49M $10.13M
-Common Stock $0.00 $0.00 $0.00 $0.00
-Accounts Payable $4.86M $6.77M $5.84M $1.35M
Payables $4.86M $6.77M $5.84M $1.35M
Total Current Liabilities $34.01M $29.76M $30.49M $8.94M
Total Liabilities $707.38M $708.29M $709.91M $370.60M
Other Non-Current Assets $3.81M $2.24M $2.21M $660,000.00
-Accumulated Depreciation -$4.13M -$3.84M -$3.54M -$2.54M
-Gross PPE $15.11M $15.44M $15.61M $9.67M
Net PPE $10.98M $11.60M $12.07M $7.13M
Total Non-Current Assets $14.79M $13.84M $14.28M $7.79M
Other Current Assets $14.29M $12.90M $13.38M $6.19M
-Short Term Investments $368.77M $391.96M $413.48M $205.44M
Total Assets $456.33M $482.56M $507.66M $233.45M
Current Accrued Expenses $5.36M $4.33M $3.49M $3.50M
Short-Term Debt and Capital Lease Obligation $1.71M $1.71M $1.71M $794,000.00
Capital Stock $0.00 $0.00 $0.00 $0.00
Stockholders' Equity -$251.05M -$225.73M -$202.26M -$137.15M
Total Equity -$251.05M -$225.73M -$202.26M -$137.15M
Other Non-Current Liabilities $805,000.00 $801,000.00 $781,000.00 $505,000.00
Convertible preferred securities $357.62M $357.62M $357.62M $357.62M
Non-Current Deferred Liabilities $309.76M $314.50M $314.99M $0.00
-Long Term Capital Lease Obligation $5.19M $5.62M $6.03M $3.54M
Total Current Assets $441.54M $468.72M $493.38M $225.67M
Long Term Debt and Capital Lease Obligation $5.19M $5.62M $6.03M $3.54M
Total Non-Current Liabilities $673.37M $678.54M $679.43M $361.66M
Current Deferred Liabilities $18.91M $14.92M $16.56M $0.00
-Current Capital Lease Obligation $1.71M $1.71M $1.71M $794,000.00
-Cash and Cash Equivalents $58.48M $63.86M $66.52M $14.03M

Discussion

No comments yet — be the first to weigh in on ADRX.

Sign in to join the discussion.

Scroll to Top